Immunotherapies have revolutionized cancer treatment, offering hope to those whose malignancies have stubbornly survived other existing treatments. Yet solid tumor cancers are often resistant to these approaches. New findings untangle one of the ways tumors evade immune detection and show how immunotherapies can be modified to tackle even these solid tumors.